Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313355695> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W4313355695 endingPage "123.7" @default.
- W4313355695 startingPage "123.7" @default.
- W4313355695 abstract "Abstract B cell Chronic Lymphocytic Leukemia (CLL), the most common leukemia in the western world, is characterized by an accumulation of abnormal B cells in the blood and lymphoid organs. Broad immunosuppression is a serious complication for these patients, with infections and secondary cancers recognized as the leading causes of morbidity and mortality. Although the immune suppression is in part due to clonotypic CLL B cells crowding immune organs, immune responses may also be suppressed by the production of soluble mediators. We and others found that CLL cells produce interleukin-10 (IL-10), a cytokine that suppresses T cell effector function. We hypothesized that this IL-10 may reduce anti-tumor T cell responses. In our studies we use human cells as well as the Eμ-Tcl1 mouse model for U-CLL, in which the oncogene Tcl1 is expressed under the immunoglobulin VH promoter and μ-enhancer. Previously, we found that IL-10R−/− T cells control CLL growth better than WT T cells in the Eμ-Tcl1 adoptive transfer model. We also saw that CLL IL-10 production is dependent on BCR signaling and activation of the transcription factor Sp-1. IL-10 production can be blocked by mithramycin (MTM), an Sp-1 inhibitor. However, MTM is not used routinely as an anti-cancer agent due to its short half-life and associated toxicities, so we prepared and tested novel analogues of MTM to reduce these effects. One of these analogues, MTM23, shows promise as it has similar potency to MTM, but does not interfere with T cell gamma-interferon production or viability. This approach is novel as current therapies for CLL do not target IL-10, or address the immunosuppression seen in CLL patients. IL-10 blockade could therefore be a strategy for harnessing anti-tumor T cells to treat CLL in humans." @default.
- W4313355695 created "2023-01-06" @default.
- W4313355695 creator A5008062466 @default.
- W4313355695 creator A5025818220 @default.
- W4313355695 creator A5036758814 @default.
- W4313355695 creator A5043984639 @default.
- W4313355695 creator A5044916901 @default.
- W4313355695 creator A5066981358 @default.
- W4313355695 creator A5074300281 @default.
- W4313355695 creator A5077557326 @default.
- W4313355695 creator A5081779643 @default.
- W4313355695 creator A5087365484 @default.
- W4313355695 date "2018-05-01" @default.
- W4313355695 modified "2023-09-25" @default.
- W4313355695 title "Approaches to reverse interleukin-10 mediated immunosuppression in chronic lymphocytic leukemia" @default.
- W4313355695 doi "https://doi.org/10.4049/jimmunol.200.supp.123.7" @default.
- W4313355695 hasPublicationYear "2018" @default.
- W4313355695 type Work @default.
- W4313355695 citedByCount "0" @default.
- W4313355695 crossrefType "journal-article" @default.
- W4313355695 hasAuthorship W4313355695A5008062466 @default.
- W4313355695 hasAuthorship W4313355695A5025818220 @default.
- W4313355695 hasAuthorship W4313355695A5036758814 @default.
- W4313355695 hasAuthorship W4313355695A5043984639 @default.
- W4313355695 hasAuthorship W4313355695A5044916901 @default.
- W4313355695 hasAuthorship W4313355695A5066981358 @default.
- W4313355695 hasAuthorship W4313355695A5074300281 @default.
- W4313355695 hasAuthorship W4313355695A5077557326 @default.
- W4313355695 hasAuthorship W4313355695A5081779643 @default.
- W4313355695 hasAuthorship W4313355695A5087365484 @default.
- W4313355695 hasConcept C203014093 @default.
- W4313355695 hasConcept C2776090121 @default.
- W4313355695 hasConcept C2777938653 @default.
- W4313355695 hasConcept C2778461978 @default.
- W4313355695 hasConcept C2778690821 @default.
- W4313355695 hasConcept C2780252810 @default.
- W4313355695 hasConcept C502942594 @default.
- W4313355695 hasConcept C86803240 @default.
- W4313355695 hasConcept C8891405 @default.
- W4313355695 hasConcept C90375314 @default.
- W4313355695 hasConceptScore W4313355695C203014093 @default.
- W4313355695 hasConceptScore W4313355695C2776090121 @default.
- W4313355695 hasConceptScore W4313355695C2777938653 @default.
- W4313355695 hasConceptScore W4313355695C2778461978 @default.
- W4313355695 hasConceptScore W4313355695C2778690821 @default.
- W4313355695 hasConceptScore W4313355695C2780252810 @default.
- W4313355695 hasConceptScore W4313355695C502942594 @default.
- W4313355695 hasConceptScore W4313355695C86803240 @default.
- W4313355695 hasConceptScore W4313355695C8891405 @default.
- W4313355695 hasConceptScore W4313355695C90375314 @default.
- W4313355695 hasIssue "1_Supplement" @default.
- W4313355695 hasLocation W43133556951 @default.
- W4313355695 hasOpenAccess W4313355695 @default.
- W4313355695 hasPrimaryLocation W43133556951 @default.
- W4313355695 hasRelatedWork W110589617 @default.
- W4313355695 hasRelatedWork W1872714075 @default.
- W4313355695 hasRelatedWork W1991601972 @default.
- W4313355695 hasRelatedWork W2047209980 @default.
- W4313355695 hasRelatedWork W2136175148 @default.
- W4313355695 hasRelatedWork W2402149178 @default.
- W4313355695 hasRelatedWork W2464086138 @default.
- W4313355695 hasRelatedWork W91094769 @default.
- W4313355695 hasRelatedWork W2185732136 @default.
- W4313355695 hasRelatedWork W2396811992 @default.
- W4313355695 hasVolume "200" @default.
- W4313355695 isParatext "false" @default.
- W4313355695 isRetracted "false" @default.
- W4313355695 workType "article" @default.